We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




RNAs Are Altered in Melanoma

By LabMedica International staff writers
Posted on 26 May 2011
A long, noncoding (lnc) RNA is elevated in melanoma cells, where it promotes cellular survival and invasion.

Scientists have discovered that levels of a relatively understudied group of RNAs–long, non-coding RNAs (lncRNAs)–are altered in human melanoma. More...
Dr. Ranjan Perera, associate professor at Sanford-Burnham Medical Research Institute (Sanford-Burnham; Orlando, FL, USA), and collaborators at the University of Queensland (Brisbane, Australia) compared lncRNAs in several laboratory cell-lines of melanoma and normal skin cells, as well as in 30 different human patient samples. They found that levels of the lncRNA, SPRY4-IT1, were particularly high in melanoma cells, but not in normal skin cells.

The study, published online May 10, 2011, in the journal Cancer Research showed that the elevated levels of SPRY4-IT1 in melanoma cells, promoted cellular survival and invasion.

To further probe the function of this lncRNA, they looked at what happens in a melanoma cell-line where SPRY4-IT1 levels are significantly reduced. Cellular growth was impaired and cell death was increased in the SPRY4-IT1-deficient melanoma cells, as compared to melanoma cells with fully functioning lncRNAs. In addition, the ability of melanoma cells to invade the extracellular matrix (an early step in cancer cell metastasis) was reduced in cells lacking SPRY4-IT1.

"The elevated expression of SPRY4-IT1 in melanoma cells, its accumulation in the cell cytoplasm, and effects on cell dynamics all suggest that increased SPRY4-IT1 may play an important role in the molecular underpinnings of human melanoma," said Prof. Perera. "Based on this information, we believe SPRY4-IT1 could be an early biomarker for the detection of melanoma."

In a separate study published in the journal PLoS ONE, in November 2010, Dr. Perera's group reported that melanoma cells have lower levels of a different non-coding RNA, called miR-211. Together, these two studies give scientists a better understanding of melanoma development, which in turn will help them design new diagnostics and therapeutics for this often-fatal disease.

Related Links:

Burnham Medical Research Institute
University of Queensland



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.